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Abstract
Background: Irreversible electroporation (IRE) is a local ablation technique utilizing high voltage, low energy direct
current to create nanopores in cell membrane which disrupt homeostasis and leads to cell death. Previous reports
have suggested IRE may have a role in treating borderline resectable and unresectable Stage 3 pancreatic tumors.
Methods: Patients with Stage 3 pancreatic ductal adenocarcinoma (PDAC) will be enrolled in either a randomized,
controlled, multicenter trial (RCT) or a multicenter registry study. Subjects enrolled in the RCT must have no
evidence of disease progression after 3 months of modified FOLFIRINOX (mFOLFIRINOX) treatment prior to being
randomization to either a control or IRE arm. Post-induction and post-IRE treatment for the control and IRE arms,
respectively, will be left to the discretion of the treating physician. The RCT will enroll 528 subjects with 264 per
arm and include up to 15 sites. All subjects will be followed for at least 24 months or until death. The registry study
will include two cohorts of patients with Stage 3 PDAC, patients who received institutional standard of care (SOC)
alone and those treated with IRE in addition to SOC. Both cohorts will be required to have undergone at least 3
months of SOC without progression prior to enrollment. The registry study will enroll 532 patients with 266 patients
in each arm. All patients will be followed for at least 24 months or until death. The primary efficacy endpoint for
both studies will be overall survival (OS). Co-primary safety endpoints will be 1) time from randomization or
enrollment in the registry to death or new onset of Grade 4 adverse event (AE), and (2 high-grade complications
defined as any AE or serious AE (SAE) with a CTCAE v5.0 grade of 3 or higher. Secondary endpoints will include
progression-free survival, cancer-related pain, quality of life, and procedure-related pain for the IRE arm only.
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Discussion: These studies are intended to provide Level 1 clinical evidence and real-world data demonstrating the
clinical utility and safety of the use of IRE in combination with chemotherapy in patients with Stage 3 PDAC.
Trial registration: Clinicaltrials.gov NCT03899636 and NCT03899649. Registered April 2, 2019. Food and Drug
Administration (FDA) Investigational Device Exemption (IDE) trial G180278 approved on May 3, 2019.
Keywords: Pancreatic ductal adenocarcinoma, Locally advanced pancreatic cancer, Irreversible electroporation,
NanoKnife system, Ablation, Modified FOLFIRINOX
Background
The incidence of pancreatic cancer has risen consistently
from 1992 to 2020, while the number of deaths due to
pancreatic cancer in the United States has also risen
proportionately [1]. There will be an estimated 57,600
patients initially diagnosed pancreatic cancer in 2020,
representing 3.2% of all new cancer cases. A total of 47,
050 deaths due to pancreatic cancer are projected to
occur in the U.S. in 2020 representing 7.8% of all cancer
deaths [1]. Median overall 5-year survival for patients
with Stage 1 and 2 pancreatic cancer has been reported
to be 24.4 months while locally advanced pancreatic
Stage 3 cancer (LAPC) has a median survival of less 1
year [2, 3]. Patients with Stage 3 pancreatic ductal
adenocarcinoma (PDAC) represent 39.2% of the nonme-
tastatic patient population with an associated 5-year sur-
vival of 10.8% [2]. The probability of survival is inversely
proportional to tumor size and the number of positive
lymph nodes [4].
The current standard of care (SOC) for stage 3 PDAC
includes systemic chemotherapy. FOLFIRINOX (com-
bination chemotherapy using 5-fluorouracil [5-FU], leu-
covorin [folinic acid], irinotecan, and oxaliplatin) has
demonstrated improved overall survival to 11.1 months
for FOLFIRINOX versus 6.4 months for gemcitabine in
metastatic pancreatic cancer, but at the cost of greater
toxicity [5]. More recently, a modified form of FOLFIRI-
NOX (without the bolus 5-FU and with a reduced dose
of irinotecan) has been shown to have an acceptable
safety profile while maintaining comparable efficacy of
FOLFIRINOX in metastatic pancreatic cancer [6]. The
National Cooperative Cancer Network (NCCN) has re-
cently added modified FOLFIRINOX (mFOLFIRINOX)
as a preferred regimen for Stage 3 pancreatic cancer pa-
tients with a good performance status (ECOG 0–1) [7].
Although radiation therapy is frequently utilized in the
United States for patients with Stage 3 pancreatic cancer,
there currently exists a dearth of level 1 evidence dem-
onstrating benefit for radiation or any other local ther-
apy modality. One of the pivotal studies for radiation
therapy in this population was the LAP07 prospective
randomized trial [8]. In this trial, patients received
induction chemotherapy with gemcitabine with or
without erlotinib and were then randomized to receive
chemoradiation therapy or continue chemotherapy.
There was no difference in the primary endpoint of OS
although there was decreased local tumor progression in
the chemoradiation arm. One major limitation of this
trial is that the induction chemotherapy used was not
consistent with the current standard of using multiagent
combination chemotherapy and it is possible that a more
effective systemic induction regimen like mFOLFIRI-
NOX may set the stage for benefit from a local interven-
tion like radiation or ablation.
The poor outcomes among patients with pancreatic
cancer has led to the pursuit of new treatment options.
Irreversible electroporation or IRE (NanoKnife System,
AngioDynamics, Inc., Latham, New York) is a non-
thermal based method for local ablation which causes
increased permeabilization of the cell membrane
through exposure of the cell to electric pulses [9]. Elec-
trodes are placed in a pattern which enables the tumor
to be encompassed by the electrical field produced, with
electric pulses irreversibly permeating the membranes
resulting in cell death. IRE may lead to better preserva-
tion of vessels, nerves, and extracellular matrix within or
close to the ablated area compared to thermal ablation
techniques [10–13].
A growing body of evidence exists on the use of the
NanoKnife System to treat pancreatic tumors, including
both borderline resectable and unresectable tumors
[14–16]. Studies have reported a median OS from diag-
nosis ranging from 14 to 27 months [17–27] and a me-
dian OS from IRE treatment ranging from 10 to 27
months [28–30]. The largest of these studies, a 200-
patient, multicenter registry of patients with stage 3
pancreatic cancer treated with IRE via an open surgical
approach, reported a median OS of 24.9 months and a
median local progression free interval of 10.7 months
[21]. Holland et al. recently reported results from a
multicenter registry which included 152 patients with
LAPC treated with IRE via an open approach at 6 dif-
ferent institutions [31]. Median OS from diagnosis,
progression-free survival (PFS), and time to progression
(TTP), all from diagnosis were 30.7 months, 22.8
months, and 27.3 months, respectively.
Narayanan et al. reported a retrospective review of 50
patients with LAPC treated with percutaneous IRE (26).
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Median OS was 27months (95% confidence interval
[CI], 22.7–32.5 months from the time of diagnosis) and
14.2 months (95% CI, 9.7–16.2 months) from the time of
IRE. Multivariate analysis demonstrated patients with
tumors ≤3 cm had significantly longer median OS than
patients with tumors > 3 cm (33.8 vs. 22.7 months from
time of diagnosis; p = 0.002, and 16.2 vs. 9.9 months
from time of IRE; p = 0.031). More recently, Ruarus et al.
reported the results of the Phase II multicenter PANF
IRE II study which prospectively enrolled 50 patients
treated with CT-guided percutaneous IRE [25]. This in-
cluded 40 patients with LAPC and 10 patients with local
recurring pancreatic cancer following resection. The me-
dian OS from diagnosis for patients with LAPC was 17
months. For patients with local recurrence, the median
OS was 16 months from the diagnosis of recurrence and
9months from IRE treatment. He et al. retrospectively
compared 36 patients treated with IRE and 40 patients
receiving radiotherapy with both groups receiving 4
months of induction chemotherapy prior to treatment
[32]. Following a Propensity Score Matching (PSM) ana-
lysis, patients in the IRE group had longer median OS
than patients receiving radiotherapy (21.6 months vs.
10.6 months) with significantly greater 1-year (71.4% vs.
41.3%) and 2 year (53.5% vs. 20.7%) OS rates (p = 0.011).
Major complications (grade 3 or higher) have been re-
ported in approximately 21 to 34% of patients treated
with IRE [16, 25]. This includes the development of por-
tal vein thrombosis, pancreatic fistulae, pancreatitis and
hematomas [15].
The above studies have paved the way for conducting
two U.S. Food and Drug Administration (FDA) approved
Investigational Device Exemption (IDE) studies to
prospectively investigate the safety and efficacy of IRE
treatment in patients with Stage 3 PDAC, with the goal
of establishing level 1 clinical evidence via a RCT and
the collection of real-world data via a parallel registry
study that facilitates the enrollment of a similar, yet
broader, patient population.
Methods
Randomized controlled trial (RCT)
The randomized, controlled, 2-arm, unblinded multicen-
ter trial will be conducted at up to 15 sites. After subjects
have been treated with 3months of mFOLFIRINOX and
there is no evidence of disease progression, they will be
randomized to either a control arm or a treatment arm of
IRE with the NanoKnife System using either an open or a
percutaneous approach. Randomization will be conducted
centrally with subjects randomized in a 1:1 ratio after as-
sessment using a study specified imaging protocol. (Fig. 1).
Post-induction treatment in the control arm and post IRE
treatment for the IRE arm will be left to the discretion of
the treating physician. The mFOLFIRINOX regimen will
consist of oxaliplatin at 85mg/m2, leucovorin at 400mg/
m2, irinotecan at 150mg/m2 all on day 1, plus 5-FU at
2.4 g/m2 starting on day 1 for 46 h. This regimen will be
repeated every 14 days. The minimum period of follow-up
for each subject will be for 24months or until death.
Study accrual is estimated to require 36months to
complete with each subject followed until 24months after
enrollment of the last subject, or death.
Registry study
The multicenter, observational registry study will include
patients with Stage 3 PDAC who received SOC alone
and those treated with IRE in addition to SOC (Fig. 2).
Both cohorts will be required to undergo at least 3
Fig. 1 Study Design: Randomized Controlled
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months of SOC without progression prior to enrollment
in the registry. The accrual time for the registry study is
24 months, and each patient will be followed-up for at
least 3 months after the study enrolls 266 patients in
each cohort. The Registry study will enroll both control
and IRE patients from sites where patients are routinely
treated with ablation using the NanoKnife System. Add-
itional control patients will also be enrolled from sites
that do not offer treatment with the NanoKnife System.
The non-NanoKnife sites will be selected to be compar-
able to the NanoKnife sites with respect to type of cen-
ter, geography, size, volume of patients with pancreatic
cancer, volume of pancreatic cancer surgeries, type of
chemotherapy, and duration of chemotherapy.
Study objectives
The primary objectives for both the RCT and registry
study are to test the hypothesis that IRE with the Nano-
Knife System improves OS in subjects with Stage 3
PDAC and to assess the safety of IRE compared to the
control arm for the RCT or SOC cohort for the registry
study. Secondary objectives include comparing PFS,
cancer-related pain and quality of life (QOL) for subjects
in the control arm versus the IRE arm and to assess
procedure-related pain in subjects in the IRE arm.
Key eligibility criteria
The RCT will be limited to subjects with cytologically or
pathologically confirmed pancreatic adenocarcinoma
that are unresectable and who meet the study’s inclu-
sion/exclusion criteria (Table 1). As compared to the
stringent eligibility requirements of the RCT, the registry
study will have broader inclusion/exclusion criteria
allowing for evaluation of real-world evidence regarding
the safety and effectiveness of NanoKnife IRE. Patients
who have received a wide variety of prior treatments
(chemotherapy, chemoradiation or other procedures) as
well as those who choose to receive the IRE treatment
rather than get randomized are eligible to participate in
the registry study. Subjects must have no evidence of
disease progression after completion of the 3 months of
induction therapy in order to participate in the RCT and
registry. Response Evaluation Criteria In Solid Tumours
1.1 (RECIST 1.1) and pancreatic cancer specific second-
ary endpoints may be used to assess radiologic and clin-
ical outcomes associated with disease progression.
Blinded reads of imaging will be performed in a central
location by external blinded readers for both the ran-
domized controlled trial and the registry study.
Study endpoints and assessments
The primary efficacy endpoint for both the RCT and the
registry study will be OS defined as the time (in months)
from randomization or enrollment in the registry to the
date of death for any reason. Co-primary safety end-
points include time (in months) from randomization or
enrollment in the registry to death or new onset of
Grade 4 AE, and the development of high-grade compli-
cations defined as any AE or SAE with a CTCAE v5.0
grade of 3 or higher.
Secondary endpoints for both studies include a) PFS
defined as the time (in months) from randomization or
enrollment in the registry to the date of first observed
disease progression (per clinical and radiologic criteria),
Fig. 2 Study design: Registry
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or death from any cause, if death occurs without docu-
mented disease progression, b) procedure-related pain in
subjects in the IRE arm, as measured by the Brief Pain
Inventory (BPI-SHORT FORM) on the day of the pro-
cedure and post-procedure days 1, 7, 14 and 30, c)
cancer-related pain assessed in the control and IRE arms
using the BPI-SHORT FORM at baseline, 3 months, 6
months and at 6-month intervals thereafter, and d) QOL
assessed in the control and IRE arms using the EQ-5D
questionnaire at baseline, 3 months, 6 months and then
at 6-month intervals for the duration of the study.
The registry study will also assess several exploratory
endpoints including chemotherapy-free days (after 3
months of SOC), the need for opioids for cancer-related
pain, OS from date of pancreatic cancer diagnosis, PFS
from date of enrollment, and identification of risk
factors and biomarkers associated with outcomes.
Additional QOL exploratory endpoints which will be
collected include rates of avoidable events associate with
chemotherapy in the IRE arm during chemotherapy free
days compared to the control arm, unplanned readmis-
sions within 30 days following discharge, and in-hospital
mortality.
Sample size and statistical considerations
Randomized controlled trial
Randomization will be conducted centrally. Concurrent
randomization to either the IRE or control arm will take
place at the completion of 3-month modified FOLFIRINOX
Table 1 Patient Inclusion and Exclusion Criteria
Key Inclusion Criteria
Randomized Controlled Multicenter Study
● Signed and dated informed consent form.
● 18 years of age and older.
● Diagnosis of unresectable Stage 3 pancreatic adenocarcinoma cancer
cytologically or pathologically confirmed per American Joint
Committee on Cancer (AJCC) staging criteria.
● Tumor evaluated as Stage 3 according to National Comprehensive
Cancer Network (NCCN) guidelines, based on radiographic imaging or
exploratory surgery.
● Maximum axial and anterior to posterior tumor dimension of ≤3.5 cm,
after receiving three months of treatment with the mFOLFIRINOX
regimen.
● Has received 3months of treatment with the mFOLFIRINOX regimen.
● Has an Eastern Cooperative Oncology Group (ECOG) performance
status of 0 or 1.
● Has an American Society of Anesthesiologists (ASA) classification of
physical health status of 1, 2, 3 or 4.
Multicenter Registry
● Signed and dated informed consent form
● 18 years of age and older
● Diagnosis of Stage 3 PC cytologically or pathologically confirmed per
American Joint Committee on Cancer (AJCC) staging criteria.
● Tumor evaluated as Stage 3 according to National Comprehensive
Cancer Network (NCCN) guidelines, based on radiographic imaging or
exploratory surgery
● Maximum axial and anterior to posterior tumor dimension of ≤3.5 cm
after standard of care.
● Has received 3months of standard of care per each participating
institution’s guidelines
● Has an Eastern Cooperative Oncology Group (ECOG) performance
status of 0 or 1.
● Has an American Society of Anesthesiologists (ASA) classification of
physical health status of 1, 2, 3 or 4.
● Are at an IRE site and are deemed eligible for IRE and receive ablation
using the NanoKnife System.
● Shows no evidence of disease progression based on NCCN guidelines
after completing 3 months of standard of care.
Key Exclusion Criteria
Randomized Controlled Multicenter Study
● Subjects who are or may be pregnant as determined by a positive
pregnancy test or breastfeeding or male or female patients of
reproductive potential who are not willing to employ highly effective
birth control from screening to 6 months after the last dose of
chemotherapy.
● Unable to tolerate general anesthetic with full skeletal muscle blockade.
● Is actively bleeding, anticoagulated, coagulopathy, or has any of the
following hematology results: hemoglobin less than10 g/dL without
the support of growth factors or transfusions; absolute neutrophil
count less than 1500 cells/mL; or platelet count less than 100,000.
● Has an implanted cardiac pacemaker, defibrillator, electronic device(s)
or implanted device(s) with metal parts in the thoracic cavity at the
time of IRE.
● Has a history of epilepsy or other neurological diseases.
● Has renal, cardiac, liver, or hematological abnormalities of concern to
the investigator.
● Has Stage 3, 4, or 5 chronic kidney disease.
● Is receiving IRE for margin accentuation.
● Has evidence of disease progression at 3 months after FOLFIRINOX
treatment.
● Participating in an interventional trial for pancreatic cancer during the
study data collection period.
● Did not meet study defined criteria for adequacy of induction
treatment at the end of the 3 months.
Multicenter Registry
● Participating in an interventional trial for pancreatic cancer during the
study data collection period.
● Pregnant or lactating patients or male or female patients of
reproductive potential who are not willing to employ highly effective
birth control from screening to 6 months after the last dose of
chemotherapy
● Unable to tolerate general anesthetic with full skeletal muscle
blockade.
● Has an implanted cardiac pacemaker, defibrillator, electronic device(s)
or implanted device(s) with metal parts in the thoracic cavity at the
time of IRE.
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administration, at participating sites, and be stratified by the
response following 3months of treatment with mFOLFIRI-
NOX (responder vs. stable disease), planned type of
IRE procedure (open or percutaneous) and planned
post-procedure treatment (chemotherapy versus radio-
therapy/ chemotherapy versus observation). A total of
444 Intent-to-treat population (ITT) subjects (with
222 subjects in each arm) are required for at least
80% power for the primary efficacy endpoint (OS),
with the expectation that there will be a total of 380
events in both arms. With the consideration of up to
16% attrition rate in both arms, and assuming a me-
dian survival of 12 months and exponential survival,
up to 528 subjects (with 264 subjects per arm) will
need to be randomized.
The sample size consideration for the primary end-
point OS was based on the assumptions that 1) there
will be a 1:1 randomization scheme, 2) median survival
will be 12 months and 16months in the control and the
IRE arm, respectively, i.e., a hazard ratio of 0.75 for IRE
versus control 3) there will be a 5% 2-sided type I error,
4) there will be an accrual period of 36 months and
follow-up period of 24 months after the study is fully en-
rolled. In addition, based on an assumption that median
times to PFS will be 6 months and 8months in the con-
trol and IRE arm, respectively, the study has at least 80%
power for analysis of the difference in the secondary
endpoint of time to PFS between the IRE and control
arms.
Registry study
The registry study will enroll 266 patients in the IRE
cohort and 266 patients in the SOC cohort in order to
achieve 90% power for analyzing both the OS and PFS
endpoints. The power calculation assumes that it will
take 24months for accrual, and all 532 patients will be
followed for at least 3 months after completion of ac-
crual. The sample size consideration was based on the
assumptions that the median OS time will be 12 months
for SOC cohort and 18 months for the IRE cohort and
there will be a 0.05 Alpha level (Type I error rate). For
the secondary effectiveness endpoint of PFS, 210 patients
will be needed per cohort for 90% statistical power as-
suming a median PFS of 8 months and 12months for
the SOC and IRE cohorts, respectively, or 116 patients
per cohort if the median PFS survival is 8 months for the
SOC cohort and 14 months for the IRE cohort.
Statistical analysis
Randomized controlled trial
There will be three analysis populations: 1) an Intent-to-
treat population (ITT) which includes all subjects random-
ized with treatment assignment based on randomization
(regardless of actual treatment received); 2) a Modified
Intent-to-treat population (mITT) which includes random-
ized subjects in the control arm who did not receive IRE
procedures, and those in the IRE arm who have undergone
the IRE procedure, excluding subjects with major protocol
deviations. Treatment assignment will be based on the ran-
domized treatment. For subjects who are randomized to
control arm but later received IRE treatment, the study data
only up to the date of IRE will be considered in this analysis
population. Those subjects randomized to the IRE arm but
did not receive IRE procedures will be excluded from this
analysis population; and 3) a Safety Population consisting of
all randomized subjects. If subjects randomized to the con-
trol arm receive IRE treatment with NanoKnife, they will
be included in the IRE safety population. Similarly, if sub-
jects randomized to the IRE arm did not receive IRE treat-
ment, they will be included in the control safety population.
For the primary efficacy endpoint, the null hypothesis
for OS is stated as H0: Scontrol = SIRE and the alternative
hypothesis is H1: Scontrol ≠ SIRE, where Scontrol is the me-
dian OS time for the control arm, and SIRE is the median
OS time for the IRE treatment arm.
The null hypothesis states that there is no difference
in median OS time post randomization between the IRE
arm and the control arm, while the alternative hypoth-
esis states there is. The trial is powered to show the
superiority of OS of 4 months in the IRE arm over the
control arm. The above null hypothesis will be tested by
a 2-sided log rank test at 0.05 significance level in the
final analysis. If the null hypothesis is rejected by the
two-sided test and the observed median OS time in the
IRE is greater than in the control arm, the alternative
hypothesis will be established and the superiority of OS
in the IRE arm will be statistically proven.
For the secondary efficacy analysis, the null hypothesis
for PFS is H0: μcontrol = μIRE with the alternative hypoth-
esis being H1: μcontrol ≠ μIRE,where μcontrol is the median
PFS time for the control arm, and μIRE is the median
PFS time for the IRE arm. This study is powered to show
the superiority of PFS of 2 months in the IRE arm over
the control arm. The above null hypothesis will be tested
by a 2-sided log rank test at 0.05 significance level only
if the result of testing the primary efficacy endpoint is
statistically significant. If the above null hypothesis is
rejected by the two-sided test and the observed median
PFS time in the IRE is greater than in the control arm,
the alternative hypothesis will be established and the su-
periority of the PFS in the IRE arm will be statistically
proven.
Analysis of the primary efficacy endpoint and key sec-
ondary endpoints will also be performed for the mITT
population as supportive analyses. Safety analysis will be
performed on the Safety population. To control the
overall type I error rate for testing efficacy endpoints, a
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fixed-sequence testing procedure will be used to test the
primary and secondary efficacy endpoints in a prede-
fined order. The test will be performed in sequence and
significance of OS endpoint is required in order to
proceed to the testing of PFS endpoint. All statistical
tests will be at the two-sided 0.05 significance level and
the corresponding p-values and 95% confidence intervals
(CIs) will be reported. Subjects alive or lost to follow-up
at the time of analysis will be censored at their last date
of follow-up. In the final analysis, OS will be compared
between the randomized treatment arms using a two-sided
log-rank test at a type I error rate of 0.05. ITT analysis will
be the primary analytic methods, supported with mITT
and Cox proportional hazards analysis. Kaplan-Meier
methods will be used to summarize survival distribution of
OS and median OS time for each treatment arm. The rela-
tive treatment effect between the IRE arm and the control
arm with respect to OS will be estimated by the hazard ra-
tio (HR) and the associated two-sided 95% CIs using the
Cox proportional hazards model.
There will be one planned interim analysis with an
early stopping rule for adverse events and for superiority
associated with the primary efficacy endpoint. Stopping
rules for adverse events will include (but will not be lim-
ited to) two IRE related ventricular arrhythmias during
the IRE procedure that require synchronized cardiover-
sion or defibrillation or one death determined by the in-
vestigator and the Data Monitoring Committee (DMC)
to be related to IRE.
There will be a single OS-based threshold for stopping
the trial for superiority using a pre-specified Haybittle-
Peto boundary with an alpha level of 0.001. If the IRE
arm demonstrates superiority over the control arm with
P-value< 0.001 following the interim analysis, the study
may be terminated early, depending on the safety profile.
Since the study will be powered based on an OS primary
endpoint, there will not be an adverse events related
threshold for stopping the trial for superiority.
The interim analysis will not be used to lead to early
termination of the study because of futility (e.g., the IRE
arm does not demonstrate superiority over the control
arm). The DMC will have the ability to make recom-
mendations after reviewing the results of the interim
analysis or through safety monitoring, and in conjunc-
tion with the study sponsor, can decide to continue or
terminate the study to save resources.
The interim analysis will be conducted when approxi-
mately 251 (66% of the total 380) deaths have been ob-
served in the overall ITT population. As part of the
interim analysis, the assumptions about the sample size
estimation will also be evaluated. The final analyses of
OS will be conducted at the 5% level of significance
when approximately 380 death events occurred. Interim
data will be evaluated by the independent DMC.
Subjects who do not have disease progression and
have not died, will be censored at the date of last tumor
assessment. Subjects with a single missing radiologic or
clinical assessment immediately prior to a visit with doc-
umented disease progression (or death) will be analyzed
as a PFS event at the time of the clinical or radiologic as-
sessment that shows progression. Subjects with two or
more consecutive missing radiologic or clinical assess-
ments immediately prior to an assessment without docu-
mented progression (or death) will be censored at the
date of last assessment when the subject was docu-
mented as progression-free prior to the first of the two
or more missing assessments. PFS will be analyzed using
similar statistical methods as that for the OS endpoint.
Pain Severity Scores and average Pain Interference
Score will be derived for each subject from BPI-SHORT
FORM questionnaire. QOL measures will be derived for
each subject from the EQ-5D questionnaire, including
the EQ Visual Analogue Scale (VAS) and EQ-5D sum-
mary index. Both absolute change and percent change
from baseline will be analyzed by treatment arm and by
study visit for all of the above.
For the primary safety endpoints, a log-rank test will
be used to compare the time (in months) from
randomization to death or new onset of Grade 4 AEs for
the two treatment arms, with data censored at the time
of loss to follow up or study discontinuation. The num-
ber and proportion of subjects with a high-grade compli-
cation defined as any AEs or SAEs with a CTCAEv5.0
grade of 3 or higher will be summarized by treatment
arm and CTCAE grade.
Registry study
There will be two analysis populations including 1) an
Effectiveness Population which consists of all enrolled
patients who will be matched by propensity score quin-
tiles, all of whom have received at least 3 months of
therapy per SOC without evidence of disease progres-
sion, and 2) a Safety Population which consists of all en-
rolled patients with the cohort assignment based on the
actual treatment received.
For the primary efficacy endpoint, the null hypothesis
for OS is stated as H0: Ssoc = SIRE and the alternative hy-
pothesis is H1: Ssoc ≠ SIRE, where Ssoc is the median OS
time for the SOC cohort, and SIRE is the median overall
survival time for the IRE cohort. For the secondary effi-
cacy analysis, the null hypothesis for PFS is H0: μsoc =
μIRE with the alternative hypothesis being H1: μsoc ≠ μIRE,
where μsoc is the median PFS time for the SOC cohort,
and μIRE is the median PFS time for the IRE arm. The
null hypothesis for each state that there is no difference
in median OS or PFS time post the initial 3 months of
therapy between the IRE cohort and the SOC cohort,
while the alternative hypothesis states there is. This
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study is powered to show the superiority of OS and PFS
in the IRE cohort over the SOC cohort. The above null
hypotheses will be tested by a 2-sided log rank test
stratified by propensity score quintiles at the 0.05 signifi-
cance level. The PFS endpoint will be tested only if the
result of testing the primary effectiveness endpoint is
statistically significant. Exploratory subgroup analyses
will include patient’s sex (male or female), and other
factors to be determined after the study team reviews
the final analyses of primary and secondary endpoints.
There will be one planned interim analysis for the
registry study, to be conducted when 50% of 266 pa-
tients in either cohort die, or per the recommenda-
tion of the DMC. The purpose of the interim analysis
is to examine accrual rate and check the assumptions
about the median survival times (i.e., 12 months for
SOC cohort and 18 months for the IRE cohort), to
ensure that the study will have sufficient power for
planned analyses.
Exploratory analyses for the registry study will include
OS from date of diagnosis, PFS from date of diagnosis,
chemotherapy-free days per 100 person-months of
follow-up after enrollment, proportion of patients
treated with opioids for cancer-related pain at 3, 6, 12,
18 and 24months after enrollment, mean Morphine
Milligram Equivalent (MME)/Day among patients using
opioids in each cohort at these time points, rates of
avoidable events associated with chemotherapy in the
IRE arm during chemotherapy free days compared to
the control arm, 30-day unplanned readmissions, in-
hospital mortality and identification of risk factors and
biomarkers associated with outcomes. These exploratory
analyses will be descriptive and, as deemed necessary,
will be stratified by propensity score quintiles, or includ-
ing propensity scores as a covariate. Unless explicitly
stated otherwise in the analysis plan, the exploratory
analyses will be based on the Effectiveness population.
The analysis method for OS from date of diagnosis and
PFS from date of diagnosis will be the same as for OS
from date of enrollment. Poisson regression model will
be used for analyzing chemotherapy-free days, and logis-
tic regression model will be used for analyzing other bin-
ary endpoints.
Discussion
A diagnosis of Stage 3 PDAC is associated with poor
outcomes and a low 5-year survival rate. The present
studies are designed to test the hypothesis that IRE
treatment with the NanoKnife System when combined
with a standard chemotherapy regimen improves overall
survival with an acceptable safety profile. Additional
goals of the study are to also provide evidence that IRE
treatment can also improve PFS, reduce cancer-related
pain and improve QOL.
These two studies will be run in parallel to collect
both level 1 clinical evidence and real-world data. This
will be accomplished via multicenter studies using both
a randomized, controlled trial design with more strin-
gent inclusion/exclusion criteria and an observational
registry enrolling of individuals which are more reflect-
ive of the broader population of patients with Stage 3
PDAC. This dual study approach will be useful towards
addressing the inherent limitations associated with using
either of these study designs for assessing the treatment
of cancer patients [32, 33]. For randomized, controlled
trials, a typical limitation is the inability to generalize the
results to a larger patient population since the study
subjects may not be representative of all cancer patients.
While registry studies can provide insights on clinical
outcomes associated with newer therapies, they have in-
herent weaknesses that impact the ability to make com-
parisons between nonrandomized patient cohorts.
The present studies are designed to contribute to the
comprehensive information and clinical evidence re-
ported to date supporting the safety and efficacy associ-
ated with IRE treatment in patients with Stage 3 PDAC.
Positive results from the study in terms of clinical effi-
cacy with an acceptable safety profile would support the
standard use of IRE in patients with Stage 3 PDAC.
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